Curative Financial Statements From 2010 to 2025

CUBT Stock  USD 0.02  0.0005  3.23%   
Curative Biotechnology financial statements provide useful quarterly and yearly information to potential Curative Biotechnology investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Curative Biotechnology financial statements helps investors assess Curative Biotechnology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Curative Biotechnology's valuation are summarized below:
Gross Profit
100.2 K
Market Capitalization
14 M
Revenue
132.3 K
Earnings Share
(0.01)
There are currently one hundred twenty fundamental signals for Curative Biotechnology that can be evaluated and compared over time across rivals. All traders should validate Curative Biotechnology's prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 13.3 M in 2025. Enterprise Value is likely to gain to about 15.4 M in 2025
Check Curative Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Curative Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 1.6 M, Depreciation And Amortization of 117.7 K or Selling General Administrative of 1.7 M, as well as many indicators such as Price To Sales Ratio of 40.38, Dividend Yield of 0.0 or Days Sales Outstanding of 267. Curative financial statements analysis is a perfect complement when working with Curative Biotechnology Valuation or Volatility modules.
  
Check out the analysis of Curative Biotechnology Correlation against competitors.
For more information on how to buy Curative Stock please use our How to Invest in Curative Biotechnology guide.

Curative Biotechnology Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Current Liabilities6.9 M6.6 M1.8 M
Slightly volatile
Other Liabilities523.9 K649.7 K529.1 K
Slightly volatile
Accounts Payable4.2 MM1.1 M
Slightly volatile
Common Stock77.2 K81.3 K475.4 K
Slightly volatile
Property Plant Equipment11.7 KK10.2 K
Slightly volatile
Total Assets3.1 MMM
Slightly volatile
Short and Long Term Debt Total2.7 M2.6 M754.4 K
Slightly volatile
Property Plant And Equipment Net4.9 K6.7 K4.6 K
Slightly volatile
Non Current Assets Total2.4 M2.3 M691.1 K
Slightly volatile
Common Stock Shares Outstanding461 M761.5 M407 M
Slightly volatile
Liabilities And Stockholders Equity3.1 MMM
Slightly volatile
Other Stockholder Equity42.3 M40.2 M13.5 M
Slightly volatile
Total Liabilities7.8 M6.6 M4.7 M
Slightly volatile
Short Term Debt2.7 M2.6 M754.4 K
Slightly volatile
Short and Long Term Debt1.3 M1.2 M540.2 K
Slightly volatile
Capital Stock49.5 K52.2 K217.5 K
Slightly volatile
Good Will129.8 K136.6 K160.6 K
Slightly volatile
Property Plant And Equipment Gross5.8 K6.2 K58.1 K
Slightly volatile
Intangible Assets1.7 M1.6 M392.7 K
Slightly volatile
Cash And Short Term Investments48.2 K50.8 K165.7 K
Very volatile
Other Current Assets480.4 K389.2 K1.4 M
Slightly volatile
Other Assets74.4 K83.7 K91.2 K
Slightly volatile
Deferred Long Term Liabilities74.4 K83.7 K91.2 K
Slightly volatile

Curative Biotechnology Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization117.7 K112.1 K30.8 K
Slightly volatile
Selling General Administrative1.7 M1.8 M991.6 K
Slightly volatile
Other Operating Expenses2.2 M2.2 M1.3 M
Slightly volatile
Total Operating Expenses2.2 M2.1 M1.3 M
Slightly volatile
Reconciled Depreciation6.6 K9.1 KK
Slightly volatile

Curative Biotechnology Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation108.7 K103.5 K25.8 K
Slightly volatile
Stock Based Compensation195.2 K205.5 K3.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio40.3852.3950.934
Slightly volatile
Days Sales Outstanding267254214
Slightly volatile
Average Payables1.6 M1.5 M611 K
Slightly volatile
Capex To Depreciation0.170.184.7501
Slightly volatile
EV To Sales71.9268.4949.9206
Slightly volatile
Inventory Turnover0.210.221.8741
Slightly volatile
Days Of Inventory On Hand1.4 K1.3 K971
Slightly volatile
Payables Turnover0.02390.02524.0441
Pretty Stable
Sales General And Administrative To Revenue0.290.560.4643
Slightly volatile
Capex To Revenue0.10.120.1296
Slightly volatile
Cash Per Share1.0E-41.0E-43.0E-4
Slightly volatile
Days Payables Outstanding14.3 K15 K48 K
Very volatile
Intangibles To Total Assets0.490.54640.545
Slightly volatile
Current Ratio0.08990.09470.9297
Very volatile
Receivables Turnover1.111.1646.0067
Pretty Stable
Capex Per Share0.00.01.0E-4
Slightly volatile
Average Receivables54.6 K52 K41.4 K
Slightly volatile
Revenue Per Share0.00.02.0E-4
Slightly volatile
Interest Debt Per Share0.00520.00490.0017
Slightly volatile
Debt To Assets1.961.01.5435
Pretty Stable
Operating Cycle1.7 K1.6 K1.2 K
Slightly volatile
Days Of Payables Outstanding14.3 K15 K48 K
Very volatile
Quick Ratio0.08990.09470.9102
Very volatile
Net Income Per E B T1.181.321.4427
Slightly volatile
Cash Ratio0.00840.00880.1434
Pretty Stable
Days Of Inventory Outstanding1.4 K1.3 K971
Slightly volatile
Days Of Sales Outstanding267254214
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.421.181.4226
Slightly volatile
Fixed Asset Turnover2.132.245.1326
Slightly volatile
Debt Ratio1.961.01.5435
Pretty Stable
Price Sales Ratio40.3852.3950.934
Slightly volatile
Asset Turnover0.180.190.6098
Slightly volatile
Gross Profit Margin0.690.870.9118
Pretty Stable

Curative Biotechnology Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap13.3 M12.7 M7.4 M
Slightly volatile
Enterprise Value15.4 M14.7 MM
Slightly volatile

Curative Fundamental Market Drivers

Cash And Short Term Investments56.4 K

About Curative Biotechnology Financial Statements

Curative Biotechnology shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Curative Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Curative Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Curative Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-3.1 M-3.3 M
Cost Of Revenue112.1 K117.7 K
Sales General And Administrative To Revenue 0.56  0.29 
Capex To Revenue 0.12  0.10 
Ebit Per Revenue(0.16)(0.17)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Curative Stock Analysis

When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.